@article{0006c12f84774017af4ee9368f372de3,
title = "Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints",
abstract = "Deficits in contrast sensitivity (CS) have been reported in Alzheimer's disease (AD). However, the extent of these deficits in prodromal AD stages, including mild cognitive impairment (MCI) or even earlier, has not been investigated. In this study, CS was assessed using frequency doubling technology in older adults with AD (n = 10), amnestic MCI (n = 28), cognitive complaints without performance deficits (CC; n = 20), and healthy controls (HC; n = 29). The association between CS and cognition was also evaluated. Finally, the accuracy of CS measures for classifying MCI versus HC was evaluated. CS deficits were found in AD and MCI, while CC showed intermediate performance between MCI and HC. Upper right visual field CS showed the most significant difference among groups. CS was also associated with cognitive performance. Finally, CS measures accurately classified MCI versus HC. The CS deficits in AD and MCI, and intermediate performance in CC, indicate that these measures are sensitive to early AD-associated changes. Therefore, frequency doubling technology-based measures of CS may have promise as a novel AD biomarker.",
keywords = "Alzheimer's disease (AD), Biomarker, Cognitive complaints, Contrast sensitivity (CS), Frequency doubling technology (FDT), Mild cognitive impairment (MCI), Vision",
author = "Risacher, {Shannon L.} and Darrell WuDunn and Pepin, {Susan M.} and MaGee, {Tamiko R.} and McDonald, {Brenna C.} and Flashman, {Laura A.} and Wishart, {Heather A.} and Pixley, {Heather S.} and Rabin, {Laura A.} and Nadia Par{\'e} and Englert, {Jessica J.} and Eben Schwartz and Curtain, {Joshua R.} and West, {John D.} and O'Neill, {Darren P.} and Santulli, {Robert B.} and Newman, {Richard W.} and Saykin, {Andrew J.}",
note = "Funding Information: This study was supported by an investigator-initiated research grant from Welch Allyn, Inc (AJS), the National Institutes of Health ( R01 AG19771 ), Alzheimer's Association ( IIRG-99-1653 from the Hedco Foundation), and Indiana Economic Development Corporation ( IEDC 87884 ) to A.J.S., National Institute on Aging ( P30 AG10133-18S1 Core Supplement to Drs. B. Ghetti and AJS), National Institutes of Health Clinical and Translational Sciences Institute Pre-doctoral Training Fellowship to S.L.R. (Training Grant TL1 RR025759 ), as well as the National Institutes of Health/National Center for Research Resources Indiana Clinical and Translational Sciences Institute ( U54 RR025761 ; C06-RR020128 ). Funding Information: Dr. Risacher receives support from the National Institutes of Health Clinical and Translational Sciences Institute Pre-doctoral Training Fellowship (Training Grant TL1 RR025759). R.W. Newman was formerly an employee of Blue Highway/Welch Allyn, Inc. He served as a consultant on the present report. Dr. Saykin receives support from the NIH (R01 CA101318, R01 AG19771, RC2 AG036535, P30 AG10133-18S1, U01 AG032984), Indiana Economic Development Corporation (IEDC #87884), and from Siemens Medical Solutions and Welch Allyn, Inc. The remaining authors report no disclosures. ",
year = "2013",
month = apr,
doi = "10.1016/j.neurobiolaging.2012.08.007",
language = "English (US)",
volume = "34",
pages = "1133--1144",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "4",
}